Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey-Reference-Cited by-同舟云学术

Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey

Published:2007-01-02 Issue:8 Volume:91 Page:910-914
ISSN:0803-5253
Container-title:Acta Paediatrica
language:en
Short-container-title:

Author:

Knobe KE,Sjörin E,Tengborn LI,Petrini P,Ljung RCR

Publisher

Wiley

Subject

General Medicine,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1651-2227.2002.tb02854.x/fullpdf

Reference28 articles.

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs [see comments];Ehrenforth;Lancet,1992

2. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII [see comments];Addiego;Lancet,1993

3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

4. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

5. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group;Sultan;Thromb Haemost,1992

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic Treatment of Children with Hemophilia in Sweden;Seminars in Thrombosis and Hemostasis;2024-03-18

2. Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications;Thrombosis Research;2022-09

3. Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea;BLOOD RESEARCH;2020-12-31

4. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis;Haemophilia;2017-06-08

5. Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models;Haemophilia;2016-08-26